Not currently recruiting at University of California Health
NL-201 in Patients With Relapsed or Refractory Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSD
- Dates
- study startedestimated completion
- Principal Investigator
- by Wanxing Chai-Ho, MD (ucla)Gregory Daniels, MD, PhD (ucsd)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientists at University of California Health
- Wanxing Chai-Ho, MD (ucla)
HS Assistant Clinical Professor, Medicine. Authored (or co-authored) 6 research publications - Gregory Daniels, MD, PhD (ucsd)
Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Neoleukin Therapeutics, Inc.
- ID
- NCT04659629
- Phase
- Phase 1 Solid Tumor Research Study
- Study Type
- Interventional
- Participants
- Expecting 252 study participants
- Last Updated